MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

Northern Tool + Equipment is bringing the high-octane excitement of Monster Jam® to the Little Rock community. On Thursday, February 20, customers will have the chance to experience the thrill-seeking ...

Utilizing new data from the Yardi® Matrix affordable housing database, the latest Yardi Matrix report on affordable housing explores the sector's current state of deliveries and ...